Zevra Therapeutics, Inc.
ZVRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -14% | 170.3% | -64.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 68.6% | 89.3% | 97.8% | 92.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -323.6% | -158.6% | -251.2% | -27.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -446.9% | -167.7% | -263.5% | -29.9% |
| EPS Diluted | -2.28 | -1.3 | -0.78 | -2.11 |
| % Growth | -75.4% | -66.7% | 63% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |